These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 37428332)

  • 1. Metastatic HER2-Positive Breast Cancer: Is There an Optimal Sequence of Therapy?
    Dempsey N; Sandoval A; Mahtani R
    Curr Treat Options Oncol; 2023 Sep; 24(9):1120-1137. PubMed ID: 37428332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic landscape of advanced HER2-positive breast cancer in 2022.
    Gupta R; Gupta S; Antonios B; Ghimire B; Jindal V; Deol J; Gaikazian S; Huben M; Anderson J; Stender M; Jaiyesimi I
    Med Oncol; 2022 Oct; 39(12):258. PubMed ID: 36224475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Current Treatment Standards and Future Perspectives.
    Dormann C
    Breast Care (Basel); 2020 Dec; 15(6):570-578. PubMed ID: 33447230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of tucatinib for HER2-positive metastatic breast cancer after HER2-targeted therapy: a network meta-analysis.
    DeBusk K; Abeysinghe S; Vickers A; Nangia A; Bell J; Ike C; Forero-Torres A; Blahna MT
    Future Oncol; 2021 Nov; 17(33):4635-4647. PubMed ID: 34463120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic management of brain metastases in HER2+ breast cancer in 2022.
    Alder L; Sammons S; Van Swearingen AED; Anders CK
    Clin Adv Hematol Oncol; 2022 May; 20(5):325-336. PubMed ID: 35579591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.
    Murthy RK; Loi S; Okines A; Paplomata E; Hamilton E; Hurvitz SA; Lin NU; Borges V; Abramson V; Anders C; Bedard PL; Oliveira M; Jakobsen E; Bachelot T; Shachar SS; Müller V; Braga S; Duhoux FP; Greil R; Cameron D; Carey LA; Curigliano G; Gelmon K; Hortobagyi G; Krop I; Loibl S; Pegram M; Slamon D; Palanca-Wessels MC; Walker L; Feng W; Winer EP
    N Engl J Med; 2020 Feb; 382(7):597-609. PubMed ID: 31825569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current and Future Management of HER2-Positive Metastatic Breast Cancer.
    Martínez-Sáez O; Prat A
    JCO Oncol Pract; 2021 Oct; 17(10):594-604. PubMed ID: 34077236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neratinib: an option for HER2-positive metastatic breast cancer.
    O'Shaughnessy JA; O'Regan R; Isaacs C
    Clin Adv Hematol Oncol; 2020 Sep; 18 Suppl 15(9):1-20. PubMed ID: 33843838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-HER2 Drugs for the Treatment of Advanced HER2 Positive Breast Cancer.
    Stanowicka-Grada M; Senkus E
    Curr Treat Options Oncol; 2023 Nov; 24(11):1633-1650. PubMed ID: 37878202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER2-positive metastatic breast cancer: a comprehensive review.
    Exman P; Tolaney SM
    Clin Adv Hematol Oncol; 2021 Jan; 19(1):40-50. PubMed ID: 33493147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Developments in the Management of Metastatic HER2-Positive Breast Cancer: A Review.
    Lebert J; Lilly EJ
    Curr Oncol; 2022 Apr; 29(4):2539-2549. PubMed ID: 35448182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial.
    Lin NU; Murthy RK; Abramson V; Anders C; Bachelot T; Bedard PL; Borges V; Cameron D; Carey LA; Chien AJ; Curigliano G; DiGiovanna MP; Gelmon K; Hortobagyi G; Hurvitz SA; Krop I; Loi S; Loibl S; Mueller V; Oliveira M; Paplomata E; Pegram M; Slamon D; Zelnak A; Ramos J; Feng W; Winer E
    JAMA Oncol; 2023 Feb; 9(2):197-205. PubMed ID: 36454580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study.
    Murthy R; Borges VF; Conlin A; Chaves J; Chamberlain M; Gray T; Vo A; Hamilton E
    Lancet Oncol; 2018 Jul; 19(7):880-888. PubMed ID: 29804905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel Therapies for the Treatment of HER2-Positive Advanced Breast Cancer: A Canadian Perspective.
    Ferrario C; Christofides A; Joy AA; Laing K; Gelmon K; Brezden-Masley C
    Curr Oncol; 2022 Apr; 29(4):2720-2734. PubMed ID: 35448196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel HER2-targeted therapies for HER2-positive metastatic breast cancer.
    Kunte S; Abraham J; Montero AJ
    Cancer; 2020 Oct; 126(19):4278-4288. PubMed ID: 32721042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How we treat patients with metastatic HER2-positive breast cancer.
    Nader-Marta G; Martins-Branco D; de Azambuja E
    ESMO Open; 2022 Feb; 7(1):100343. PubMed ID: 34995893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Guideline Update.
    Giordano SH; Franzoi MAB; Temin S; Anders CK; Chandarlapaty S; Crews JR; Kirshner JJ; Krop IE; Lin NU; Morikawa A; Patt DA; Perlmutter J; Ramakrishna N; Davidson NE
    J Clin Oncol; 2022 Aug; 40(23):2612-2635. PubMed ID: 35640077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic therapy for metastatic HER2-positive breast cancer.
    Bredin P; Walshe JM; Denduluri N
    Semin Oncol; 2020 Oct; 47(5):259-269. PubMed ID: 32896428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tucatinib Combination Treatment After Trastuzumab-Deruxtecan in Patients With ERBB2-Positive Metastatic Breast Cancer.
    Frenel JS; Zeghondy J; Guérin-Charbonnel C; Mailliez A; Volant E; Poumeaud F; Patsouris A; Arnedos M; Bailleux C; Cabal J; Galland L; de Nonneville A; Guiu S; Dalenc F; Pistilli B; Bachelot T; Pierga JY; Le Du F; Bocquet F; Larrouquere L; Loirat D
    JAMA Netw Open; 2024 Apr; 7(4):e244435. PubMed ID: 38568692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis.
    Curigliano G; Mueller V; Borges V; Hamilton E; Hurvitz S; Loi S; Murthy R; Okines A; Paplomata E; Cameron D; Carey LA; Gelmon K; Hortobagyi GN; Krop I; Loibl S; Pegram M; Slamon D; Ramos J; Feng W; Winer E
    Ann Oncol; 2022 Mar; 33(3):321-329. PubMed ID: 34954044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.